Info

Diabetes Connections | Type 1 Diabetes

The T1D news show you've been waiting for! Long-time broadcaster, blogger and diabetes mom Stacey Simms interviews prominent advocates, authors and speakers. Stacey asks hard questions of healthcare companies and tech developers and brings on "everyday' people living with type 1. Great for parents of T1D kids, adults with type 1 and anyone who loves a person with diabetes.
RSS Feed Subscribe in Apple Podcasts
Diabetes Connections | Type 1 Diabetes
2024
March
February
January


2023
December
November
October
September
August
July
June
May
April
March
February
January


2022
December
November
October
September
August
July
June
May
April
March
February
January


2021
December
November
October
September
August
July
June
May
April
March
February
January


2020
December
November
October
September
August
July
June
May
April
March
February
January


2019
December
November
October
September
August
July
June
May
April
March
February
January


2018
December
November
October
September
August
July
June
May
April
March
February
January


2017
December
November
October
September
August
July
June
May
April
March
February
January


2016
December
November
October
September
August
July
June
May
April
March
February
January


2015
December
November
October
September
August
July
June
May


Categories

All Episodes
Archives
Categories
Now displaying: Page 6
Sep 13, 2022

Doug Scalia has completed 25 marathons in 15 states. He’s about to add three more to his list, including the New York City Marathon as part of a team of people with type 1. He knows it sounds like an impossible feat for many, but he says anyone can do it! Doug was diagnosed as a young adult and he’s also played in the World Series of Poker so we have a lot to talk about.

This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider.

Learn more about Beyond Type Run and Doug's team

Check out Stacey's book: The World's Worst Diabetes Mom!

Join the Diabetes Connections Facebook Group!

Sign up for our newsletter here

Episode Transcription Below (or coming soon!)

Please visit our Sponsors & Partners - they help make the show possible!

*Click here to learn more about OMNIPOD*

*Click here to learn more about AFREZZA*

*Click here to learn more about DEXCOM*

Sep 9, 2022

It’s in the news! The top stories and headlines around the diabetes community this week include: A new way to sneak islet cells into the body without needing immunosuppressive drugs, routinely checking young children for T1D markets before symptoms show up, a non invasive way to measure blood glucose uses Radio Frequency, a DIY movement publishes in the New England Journal of Medicine and more!

Check out Stacey's book: The World's Worst Diabetes Mom!

Join the Diabetes Connections Facebook Group!

Sign up for our newsletter here

Episode Transcription Below (or coming soon!)

Please visit our Sponsors & Partners - they help make the show possible!

*Click here to learn more about OMNIPOD*

*Click here to learn more about AFREZZA*

*Click here to learn more about DEXCOM*

Hello and welcome to Diabetes Connections In the News! I’m Stacey Simms and these are the top diabetes stories and headlines of the past seven days.
XX
In the news is brought to you by T1D Exchange! T1D Exchange is a nonprofit organization dedicated to improving outcomes for the entire T1D population.
https://t1dexchange.org/stacey/
XX
French biopharma company Adocia has established a first proof of concept for its AdoShell Islets implant. This was in rats.. but they achieved glycemic control without insulin injections and without immunosuppressive drugs for four months.
AdoShell Islets is an immuno-protective synthetic biomaterial that secrets insulin in response to blood glucose levels. The physical barrier formed by the AdoShell biomaterial allows the implanted cells to be invisible to the host’s immune system while allowing the necessary physiological exchanges to occur for the survival and function of the islets.
These researchers are optimistic that their unique approach can be translated from one species to another.
https://www.labiotech.eu/trends-news/adocia-implants-diabetes/
XX
Can starting a closed loop system right away help keep kids with type 1 in the honeymoon stage longer? New study says.. probably not.
The latest findings are from the Closed Loop From Onset in Type 1 Diabetes (CLOuD) trial, a multicenter, open-label, parallel-group, randomized study, published online September 7 in the New England Journal of Medicine by Charlotte K. Boughton, PhD, and colleagues.
In CLOuD, 97 youths aged 10-17 years were randomized to hybrid closed-loop therapy or standard insulin therapy (control) within 21 days of type 1 diabetes diagnosis. I found this a bit confusing, in the standard insulin therapy groups, participants could switch to insulin pump therapy or use flash or continuous glucose monitoring (CGM) or approved closed-loop systems if clinically indicated. So this isn’t comparing an AID system to MDI.
At 12 months, there were no differences after a mixed-meal tolerance test, with levels declining in both groups and dropping further by 24 months. Interestingly, they said glycemic control didn’t differ significantly between the two groups.

https://www.medscape.com/viewarticle/980356
XX
Moving closer to a non-invasive way to measure blood glucose. The GlucoRx BioXensor uses radio frequency technology alongside a multiple sensor approach to measure blood glucose levels every minute. This looks to be about the size of a Libre 3 or Dexcom G7..
It’s said to have smart alarms and remote monitoring capability and just sticks on the skin. The MARD is 10 point 4, which is less accurate than CGMs on the market now, but much better than any other noninvasive device to make it this far. In addition to measuring blood glucose the makers say it can measure oxygen levels, ECG, respiration rate, heart rate, temperature, activity, sleep, and early fall detection.
Pivotal clinical study later this year and then the say they’ll submit for European approval.
https://www.med-technews.com/news/latest-medtech-news/glucorx-and-cardiff-university-to-bring-out-non-invasive-con/
XX
RESEARCHERS in Oxford have launched the first UK study in the general population to test for early markers of type 1 diabetes, before children develop symptoms or need insulin. They’re offering a finger stick test when children have their pre-school vaccination. Very small start, only 60 kids, but these researchers say with a recent, more accurate test to check for markers early on, they hope to find more children before DKA sets in.
https://www.oxfordmail.co.uk/news/20977659.oxford-scientists-launch-study-early-markers-type-1-diabetes-children/
XX
The first Randomized Controlled Trial on open source automated insulin delivery (AID) is now published in a peer-reviewed medical journal. Big news for and from the we are not waiting crowd.
The CREATE Trial evaluated the efficacy and safety of an open-source system using the OpenAPS algorithm in a modified version of AndroidAPS. This study included children and adults and found that across all ages, time in range was 14 percent higher than those who used commercial hybrid closed loop systems. There’s more to it, and I”ll link it up, but this study concluded that a widely used open-source AID solution, works and is safe. Congrats to Dana Lewis and all the researchers involved.
https://diyps.org/2022/09/07/nejm-publishes-rct-on-open-source-automated-insulin-delivery-openaps-algorithm-in-androidaps-in-the-create-trial/
XX
Back to the news in a moment but first..
The T1D Exchange Registry is a research study conducted online over time, designed to foster innovation and improve the lives of people with T1D. The platform is open to both adults and children with T1D living in the U.S. Personal information remains confidential and participation is fully voluntary. Once enrolled, participants will complete annual surveys and have the opportunity to sign up for other studies on specific topics related to T1D. The registry aims to improve knowledge of T1D, accelerate the discovery and development of new treatments and technologies, and generate evidence to support policy or insurance changes that help the T1D community. By sharing opinions, experiences and data, patients can help advance meaningful T1D treatment, care and policy.
The registry is now available on the T1D Exchange website and is simple to navigate, mobile and user-friendly. For more information or to register, go to www.t1dregistry.org/stacey
XX

Medtronic is waiting for FDA clearing of the new 780G.. already approved in Europe. New study results published in The Lancet Diabetes & Endocrinology, Medtronic announced Thursday put the AID pump up against multiple daily injections plus CGM. Small study, 82 people, all with an A1C over 8. After using the 780G for six months, the group saw a reduction of 1.4 percent in their levels with a quarter of that group dropping their A1C below 7. None of the MDI group dropped to that level. Time in range saw most improvement overnight.
The MiniMed 780G system has been cleared in Europe since 2020. Medtronic submitted it to the FDA for U.S. approval in the spring of 2021 but is still awaiting a decision, slowed down by the roadblocks caused by a late 2021 warning letter from the agency that called out quality control issues at the California headquarters of its diabetes business.
https://www.fiercebiotech.com/medtech/medtronics-new-minimed-insulin-pump-adds-27-boost-time-range-study-finds
XX
Change at one of the top posts at Dexcom. Jake Leach moves from Chief Technology Officer to Chief operating officer. He’s been at the company since 2004 to work on the first commercial Dexcom CGM system. He’s been a frequent guest of the show and we hope that continues.
https://www.businesswire.com/news/home/20220831005236/en/DexCom-Promotes-Jake-Leach-to-Chief-Operating-Officer
XX
Next week we’re looking ahead to the New York City Marthong. Beyond Type 1 puts together a gret team each year and I’m taking to one of the runners. He’s also nabbed a spot in the world series of poker – which do you think is tougher on his type 1 diabetes? This past episode is all about Omnipod 5 – a panel of people who’ve sued it for a few weeks now.. and the director of medical affairs to answer your questions.
Listen wherever you get your podcasts
That’s In the News for this week.. if you like it, please share it! Thanks for joining me! See you back here soon.

Sep 6, 2022

Omnipod 5 was approved earlier this year and just rolled out to a wider release. So how is the first tubeless automated insulin delivery system doing in the real world? We put together a panel of early adopters and got their feedback. That was great, but it brought up quite a few questions, so we reached out to Omnipod for clarification and follow up. The result is a super-sized episode full of info!

Our panel: Liat Kochavi, mother an almost-8-year-old with T1D, Stephanie Williams, mother of a teen with type 1, and Sam Durante who was diagnosed with type 1 just before she turned 16. You'll also here from Insulet's Director of Medical Affairs Alex Nyugen, RD, CDCES.

FYI, we were fortunate to speak with Insulet earlier this year, just after the FDA approval, and really went point by point through Omnipod 5. So we’re not rehashing everything here. If you missed that episode, here's the link: Omnipod 5 interview from Feb 2022

Check out Stacey's book: The World's Worst Diabetes Mom!

Join the Diabetes Connections Facebook Group!

Sign up for our newsletter here

-----

Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners!
-----

Episode Transcription Below (or coming soon!)

Please visit our Sponsors & Partners - they help make the show possible!

*Click here to learn more about OMNIPOD*

*Click here to learn more about AFREZZA*

*Click here to learn more about DEXCOM*

Sep 2, 2022

It’s in the news! The top stories and headlines around the diabetes community this week include new progress in the quest for oral insulin to treat type 1, a new study says a common type 2 diabetes drug may help those with serious heart condition, a look at teen brains and T1D, NSAID and type 2 and more!

Learn about the T1d Exchange: www.t1dexchange.org/stacey 

Check out Stacey's book: The World's Worst Diabetes Mom!

Join the Diabetes Connections Facebook Group!

Sign up for our newsletter here

-----

Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners!
-----

Episode Transcription Below (or coming soon!)

Please visit our Sponsors & Partners - they help make the show possible!

*Click here to learn more about OMNIPOD*

*Click here to learn more about AFREZZA*

*Click here to learn more about DEXCOM*

Hello and welcome to Diabetes Connections In the News! I’m Stacey Simms and these are the top diabetes stories and headlines of the past seven days.
XX
In the news is brought to you by T1D Exchange! T1D Exchange is a nonprofit organization dedicated to improving outcomes for the entire T1D population.
https://t1dexchange.org/stacey/
XX
Our top story.. very early on here, but some progress in oral insulin for type 1. A team at University of British Columbia has developed a different kind of tablet that isn't made for swallowing, but instead dissolves when placed between the gum and cheek. This method delivered all the insulin to the liver without wasting or decomposing any insulin along the way. That’s a big change from earlier studies and methods. The oral tablets absorb after about half an hour and last for up to four hours.. long way to go, no human trials yet. The the lead researcher on this project has a father with type 1 .
https://www.sciencedaily.com/releases/2022/08/220830093215.htm?fbclid=IwAR1AzjI5UJma9I6g4hST044FS0MbJnUA0EXCmKXyhcOiOKL-ckIQTO4h8dY
XX
The type 2 diabetes drug dapagliflozin might also be used to help people with heart failure. A new study at Brigham and Women's Hospital showed that dapagliflozin – sold under the brand name Farxiga - reduced the risk of a cardiovascular death, or worsening heart failure, regardless of ejection fraction. Ejection fraction is a term that basically refers to how much blood is pumped out by the left ventricle of the heart each time it contracts. That’s important because this drug has already been shown to help people who have the reduced pumping. And that’s a lot more people. Big study here, more than 12-thousand people with lots of ages and races, benefits consistent throughout.
https://www.bostonglobe.com/2022/08/29/business/brigham-womens-researchers-say-diabetes-drug-helps-reduce-heart-failure/
XX
I hesitate to bring this study up, but it’s gotten a lot of attention this week. It shows tight control of blood sugar in teens with Type 1 diabetes may help reduce the disease’s damaging effects on the brain. But this small study from Nemours Children’s Health, Jacksonville and Stanford University School of Medicine didn’t release any numbers, n other words, it’s not clear what they mean by tight control or at what level they’re referring to for brain issues. Their findings to indicate that automated hybrid closed loop systems work really well and that better glucose control can actually improve brain structure and function in teens with type 1. I’ve reached out to this group and we’re working on getting more information in a future episode.
https://neurosciencenews.com/blood-sugar-brain-diabetes-21328/
XX
Very early on here.. but an Indiana startup says they have a potentially game changing type 1 drug in development. In T1D, the body’s immune system causes destruction of beta cells, and as a result, they eventually stop producing insulin. These researchers say their models show thy can take what were thought to be dead beta cells, which are actually sleeping beta cells, and increase their insulin secretion and, basically, get them back to a functional state.” They’re focusing on a calcium imbalance within the beta cell and designing molecules to correct that calcium imbalance, ultimately returning the pancreas to a healthy state. JDRF has given them a big grant for a two year project, hopefully getting them to clinical trials.
https://www.insideindianabusiness.com/articles/startup-awarded-nearly-1m-to-advance-diabetes-drug
XX
People with type 2 diabetes might face a substantially increased risk of heart failure if they take ibuprofen or some other type of nonsteroidal anti-inflammatory drug (NSAID), accord to a new Danish study.
Short-term NSAID use increased risk of hospitalization for heart failure by 43% in people with type 2 but no previous heart problems. This was a large but preliminary study presented at the European Society of Cardiology's annual meeting. NSAIDs increased the risk of heart failure even more in type 2 diabetics who were 80 or older (78%) or who had high blood sugar levels (68%), the results showed. Those who'd never used an NSAID before had the worst reaction, with their heart failure risk nearly tripling. Type 2 diabetics should consult with their doctor before taking any pain medicine, the doctors said. Other types of pain meds -- specifically acetaminophen (Tylenol) -- should be safe for them to use.
https://www.usnews.com/news/health-news/articles/2022-08-24/certain-painkillers-raise-heart-failure-risk-in-people-with-type-2-diabetes

XX
Back to the news in a moment but first..
The T1D Exchange Registry is a research study conducted online over time, designed to foster innovation and improve the lives of people with T1D. The platform is open to both adults and children with T1D living in the U.S. Personal information remains confidential and participation is fully voluntary. Once enrolled, participants will complete annual surveys and have the opportunity to sign up for other studies on specific topics related to T1D. The registry aims to improve knowledge of T1D, accelerate the discovery and development of new treatments and technologies, and generate evidence to support policy or insurance changes that help the T1D community. By sharing opinions, experiences and data, patients can help advance meaningful T1D treatment, care and policy.
The registry is now available on the T1D Exchange website and is simple to navigate, mobile and user-friendly. For more information or to register, go to www.t1dregistry.org/stacey
XX
We told you about The Human Trial, Watch this gripping new documentary about the brave men and women who volunteer to test a radical new treatment for type 1 diabetes. n 2011, Lisa Hepner and her husband Guy Mossman heard about a radical stem cell treatment for diabetes, a disease that shockingly kills more than five million people each year. Driven by a desire to cure Lisa of her own type 1 diabetes (T1D), the filmmakers were given unprecedented, real-time access to a clinical trial — only the sixth-ever embryonic stem cell trial in the world. What follows is an intimate journey with the patients and scientists who put themselves on the line to be first.
Now, in partnership with Beyond Type 1 & JDRF , they’re offering the film for free. You are urged to make a donation to JDRF when you click over, there is an option to select zero,
https://watch.showandtell.film/watch/the-human-trial-beyond-type-1
XX
Next week we’ve got a great episode all about Omnipod 5 in the real world. I spoke to a panel of moms and a young adult using the system. And we’ve got Insulet’s Director of Medical affairs addressing the questions that come up. This past episode is with my son Benny, talking about what it was like to spend 8 weeks away at non diabetes camp without any remote monitoring from us.
Listen wherever you get your podcasts
That’s In the News for this week.. if you like it, please share it! Thanks for joining me! See you back here soon.

Aug 30, 2022

Stacey's son spent the summer away at regular, non-diabetes sleepaway camp. 8 weeks managing all of his own care, with no remote monitoring. You had a lot of questions, including how he manages overnight lows:

Benny is 17, he was diagnosed just before he turned two and, as usual, he has a lot to say. He had quite a few adventures at camp, but everything turned out okay. We get his take on independence, responsibility and a glimpse into how a teen with type 1 thinks.

This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider.

Check out Stacey's book: The World's Worst Diabetes Mom!

Join the Diabetes Connections Facebook Group!

Sign up for our newsletter here

-----

Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners!
-----

Episode Transcription Below (or coming soon!)

Please visit our Sponsors & Partners - they help make the show possible!

*Click here to learn more about OMNIPOD*

*Click here to learn more about AFREZZA*

*Click here to learn more about DEXCOM*

Aug 26, 2022

It’s in the news! The top stories and headlines around the diabetes community this week include a new attempt to have fewer misdiagnoses of type 2 (when it's really type 1) diabetes, a new approval for Omnipod 5 down to two years old, a look at the endocrinologist shortage in the US, a milestone for Tandem and more!

Check out Stacey's book: The World's Worst Diabetes Mom!

Join the Diabetes Connections Facebook Group!

Sign up for our newsletter here

-----

Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners!
-----

Episode Transcription Below (or coming soon!)

Please visit our Sponsors & Partners - they help make the show possible!

*Click here to learn more about OMNIPOD*

*Click here to learn more about AFREZZA*

*Click here to learn more about DEXCOM*

Hello and welcome to Diabetes Connections In the News! I’m Stacey Simms and these are the top diabetes stories and headlines of the past seven days.
XX
In the news is brought to you by T1D Exchange! T1D Exchange is a nonprofit organization dedicated to improving outcomes for the entire T1D population.
https://t1dexchange.org/stacey/
XX
New effort to avoid the very common misdiagnosis of type 2 when it’s actually type 1. JDRF and a a company called IQVIA are seeing if artificial intelligence can be used here. IQVIA used machine learning to look at data from individuals diagnosed with T2D and then, later, diagnosed with T1D within a specific time frame. The big problem, the company says, is that medical records are often incomplete and are compiled using different standards and formats. They call it a good starting point though. Earlier studies have shown that possibly 40-percent of adults with new onset type 1 are first misdiagnosed with type 2.
https://www.jdrf.org/blog/2022/08/11/iqvia-algorithm-for-misdiagnoses/

XX
New UK study about COVID, diabetes and kids.. shows there was an increase in new cases and in DKA. This was from March 2020 to February of 2021, compared to same time the previous year. This was a large study, looking back at cases across 49 sites.
There was a 17% increase in new-onset diabetes from Year 1 to Year 2, mostly of type 1 diabetes. ED visits for DKA dropped by 31.9% during the pandemic year among patients with existing diabetes. There was a 43% increase in severity of new-onset disease from Year 1 to Year 2, with severe DKA increasing by 79% (P < .001) and intensive care admissions by 89% (P < .05 There were limitations to this study, the biggest is that data was only captured for those who went to the emergency room. The question of whether SARS-CoV-2 can trigger new-onset diabetes remains unanswered.

https://www.medscape.com/viewarticle/979381#:~:text=There%20was%20a%2017%25%20increase,by%2079%25%20(P%20%3C%20.
XX
Omipod 5 is now FDA approved for kids as young as two.
Omnipod 5, the first tubeless automated insulin delivery (AID) system in the U.S., was originally cleared for use in individuals aged six and older in January 2022. That makes Omnipod 5 the only AID approved for the toddler set. Tandem’s Control IQ ia approved down to age 6 and Medtronic 780G down to age 7
https://www.businesswire.com/news/home/20220822005158/en/Insulet-Announces-FDA-Clearance-of-Omnipod%C2%AE-5-for-Children-Aged-Two-Years-and-Older-with-Type-1-Diabetes
XX
Milestone from Tandem they say that in the first month since the new mobile bolus feature was released, users have delivered more than 1 million insulin boluses. The company said in a news release that it is the first-ever FDA-cleared smartphone application capable of initiating insulin delivery on both iOS and Android operating systems. The company added that it is now available on approximately 30 different devices.

https://www.drugdeliverybusiness.com/tandem-diabetes-app-insulin-bolus-million/

XX
What looks like an editorial in a publication called Stability Health caught my eye. It’s all about the shortage of endocrinologists in the US. Right now there are only 8-thousand in practice across the whole country.
Endocrinologists receive the lowest compensation of all internal medicine (IM) specialties — lower even than practicing general internists — and 76–89% of medical students graduate with astronomical debt.
Additionally, these clinicians often make themselves available outside of their office hours. But since this time may not be billable, it is often not supported in salaried compensation.
Separately (but related), in 2016, 71% of entrants to the field of endocrinology were female. Due to America’s long-standing gender wage gap, this may be a contributing factor in wage stagnation.
Roughly 85% of Americans with diabetes rely on a general practitioner for their care. I’ll link up the column so you can take a look.
https://stabilityhealth.com/endocrinologist-shortage/?fbclid=IwAR0jx-nSiOL2UccmoJ9H74SnC6l3M5CCppecGcQ2t2M_zc7U-ydOj4JxfQ4#:~:text=Today%2C%2034.2%20million%20Americans%20are,currently%20practice%20in%20the%20U.S
XX
Update on one of the CGM smartwatches we’ve been keeping an eye on.. the K-Watch Glucose CGM watch is being tested by a French Company. They had their first clinical trials last year and got results this summer. the first run had a MARD of 29-percent.. brought down to a much better 16-percent. MARD is of course Mean Absolute Relative Difference to a calibrated meter and the gold standard right now is under 10 with Dexcom and Libre’s next offerings closer to 8.. so a way to go here.
https://www.notebookcheck.net/Painless-K-Watch-Glucose-blood-free-CGM-smartwatch-produces-positive-first-in-human-trial-results-as-PKvitality-targets-2024-for-availability.642380.0.html
XX
Back to the news in a moment but first..
The T1D Exchange Registry is a research study conducted online over time, designed to foster innovation and improve the lives of people with T1D. The platform is open to both adults and children with T1D living in the U.S. Personal information remains confidential and participation is fully voluntary. Once enrolled, participants will complete annual surveys and have the opportunity to sign up for other studies on specific topics related to T1D. The registry aims to improve knowledge of T1D, accelerate the discovery and development of new treatments and technologies, and generate evidence to support policy or insurance changes that help the T1D community. By sharing opinions, experiences and data, patients can help advance meaningful T1D treatment, care and policy.
The registry is now available on the T1D Exchange website and is simple to navigate, mobile and user-friendly. For more information or to register, go to www.t1dregistry.org/stacey
XX
Association of Diabetes Care and Education Specialists gave their lifetime Achievement Award to Dr. Kenneth Moritsugu, former surgeon general of the United States. Many of you may know him as the Chairman of the Board of Children with Diabetes you see him at Friends for Life and other events. He’s been involved with lot of national diabetes groups and effort – he was diagnosed with LADA at age 55. He’s also been a guest of this show.. so congrats Dr. Moritsugu.
https://www.healio.com/news/endocrinology/20220814/a-lifetime-of-service-a-conversation-with-kenneth-moritsugu-md-mph-facpm-faade?fbclid=IwAR2DyFSAyxCqeGMpmGHAi1FG1swihxFAPe-WveCaCP6NJrcUd0rFioBedQU
XX
Next week we’re talking back to school! The wonderful diabetes educator Anna Sabino from Finding Smiles coaching will join me to talk 504, remote monitoring, supplies and lots more. The long format episode out right now is with Patients For Affordable Drugs about the bill that passed the Senate this week. The insulin copay cap was removed, but what does it really mean for medication prices?
Listen wherever you get your podcasts
That’s In the News for this week.. if you like it, please share it! Thanks for joining me! See you back here soon.

Aug 23, 2022

Back to school can be one of the most stressful times for parents of kids with T1D and it’s okay to admit that. This week, Anna Sabino, of Finding Smiles Coaching, a diabetes educator who lives with type 1, joins Stacey to help you out! We’re going to go through 504s, school supplies, remote monitoring, last minute issues and set you up for long term success.

This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider.

More about Anna, including a great special she has for parents and families right now: https://www.findingsmilescoaching.com/

ADA Safe at School: https://diabetes.org/tools-support/know-your-rights/safe-at-school-state-laws

504 plan examples: https://diabetes.org/tools-support/know-your-rights/safe-at-school-state-laws/written-care-plans/section-504-plan

Check out Stacey's book: The World's Worst Diabetes Mom!

Join the Diabetes Connections Facebook Group!

Sign up for our newsletter here

-----

Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners!
-----

Episode Transcription Below (or coming soon!)

Please visit our Sponsors & Partners - they help make the show possible!

*Click here to learn more about OMNIPOD*

*Click here to learn more about AFREZZA*

*Click here to learn more about DEXCOM*

Aug 19, 2022

It's in the news! The top stories and headlines around the diabetes community this week include: People on Medicare should see insulin prices capped, A look at whether the tuberculosis vaccine prevented Covid in people with type 1 diabetes, Tandem's CEO has some news about their tiny Mobi pump, students create non-invasive glucose monitoring, and some progress on smart insulin.

Learn more about the T1D Exchange: https://t1dexchange.org/stacey/

Check out Stacey's book: The World's Worst Diabetes Mom!

Join the Diabetes Connections Facebook Group!

Sign up for our newsletter here

-----

Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners!
-----

Episode Transcription Below (or coming soon!)

Please visit our Sponsors & Partners - they help make the show possible!

*Click here to learn more about OMNIPOD*

*Click here to learn more about AFREZZA*

*Click here to learn more about DEXCOM*

Hello and welcome to Diabetes Connections In the News! I’m Stacey Simms and these are the top diabetes stories and headlines of the past seven days.
XX
In the news is brought to you by T1D Exchange! T1D Exchange is a nonprofit organization dedicated to improving outcomes for the entire T1D population.
https://t1dexchange.org/stacey/
XX
The Inflation Reduction act is now law.. and that means a big change for Medicare patients. Among other things, it limits insulin copays to $35 per month for Medicare Part D beneficiaries starting in 2023 and caps annual out-of-pocket cap on Part D prescription drugs at 2-thousand dollars starting in 2025. Medicare will also now have the ability to negotiate the costs of certain prescription drugs. Democrats say they will try to bring a stand alone proposal to ap the price of insulin for a broader population this fall.
XXDid the Tuberculosis vaccine protect people with type 1 from Covid and other infectious diseases? Researchers at Harvard Medical School and Massachusetts General Hospital have published a new paper looking at the BCG or tuberculosis vaccine. In a double-blind, placebo-controlled study of patients with type 1 diabetes conducted at the start of the pandemic, before COVID vaccines were available, only 12.5 percent of placebo-treated individuals and 1 percent of BCG-treated individuals had confirmed COVID-19, yielding a vaccine effectiveness of 92 percent.
The BCG-vaccinated group also displayed protective effects against other infectious diseases, including fewer symptoms, lesser severity and fewer infectious disease events per patient. No BCG-related systemic adverse events occurred.
The participants in the COVID trial had previously enrolled in a clinical trial testing the effectiveness of the BCG vaccine for type 1 diabetes. Participants in the test group had received multiple vaccinations before the onset of the pandemic in early 2020.
https://hms.harvard.edu/news/tb-drug-vs-covid

XX
Students at the American University in Cairo have developed a device that non-invasively measures blood glucose levels, winning first place in 2022 Johns Hopkins Healthcare Design Competition. The device uses near-infrared spectroscopy (speck-troh-sku-pee). It’s called GlucoClip and there’s also a mobile app. . The project took a year, with the team having designed a prototype and testing it on more than 100 people. Amazing that this took students less than a year.. we’ll see if the large commercial companies can accomplish getting something like this to the marketplace.
https://www.egyptindependent.com/auc-students-win-first-place-at-johns-hopkins-healthcare-design-competition-2022/
XX
Interesting progress on glucose-responsive insulin, also called smart insulin. These researchers envision ultra-stable proteins containing a glucagon analog “stapled” to an insulin analog. Preliminary studies are moving along at Indiana University. As the name indicates, this would be insulin that only responds when there is too much glucose in the blood, making the risk of low blood sugar much less likely. Nice to see some options may be possible, last year Lilly bought Protomer Technologies which had smart insulin in pre-clinical development.
https://diabetesresearchconnection.org/projects/fusion-protein/
XX
New CEO over at Beta Bionics – the company behind the iLet Bionic Pancreas, currently in front of the FDA. Sean Saint will be the new CEO, Martha Goldberg Aronson was interim, we talked to her for the podcast a few months ago, will remain on the Beta Bionics Board of Directors. Saint is an engineer, entrepreneur, diabetes technologist and innovator, and lives with type 1. He started at Medtronic and ahs also been at Dexcom and Tandem. It was after working at all those diabetes companies that he developed type 1 as an adult.. and founded Companion Medical, maker of the InPen. Really interesting story and I hope he’ll come on the podcast soon.
https://www.globenewswire.com/news-release/2022/08/15/2498485/0/en/Beta-Bionics-Appoints-Sean-Saint-as-CEO-and-Board-Member.html

XX
But with the troubles of the second quarter solidly in the rearview mirror, Tandem is back in optimist mode, with a rosy outlook toward sales of both existing and upcoming technologies.
Chief among the latter category is the Mobi insulin pump. The device is about half the size of Tandem’s flagship t:slim pump and can be fully controlled by a user’s smartphone. It’ll also represent “the first novel form factor launched in our space since we introduced t:slim a decade ago,” Sheridan said on the call.
“We are in the final stages of testing, as well as drafting the submission, and intend to submit a 510(k) to the FDA this quarter,” the chief executive said. He noted that Tandem is already preparing for the pint-sized pump’s commercial launch following FDA clearance, which it’s tentatively expecting to snag in the first half of 2023.
In the meantime, Sheridan said Tandem is also working closely with partners Dexcom and Abbott to integrate its insulin pumps with their newest continuous glucose monitors: Abbott’s FreeStyle Libre 3, which was cleared by the FDA just a few months ago, and Dexcom’s G7 device, whose own FDA review is still underway after an agency request for more information.
RELATED

https://www.fiercebiotech.com/medtech/tandem-lines-fda-review-new-pint-sized-insulin-pump-amid-lower-expected-sales
XX
Possible new way to look for type 2 diabetes before there are any severe symptoms. Researchers from the University of Geneva found that a decline in one molecule indicates a loss of functional beta cells. This molecule, which can be easily detected by a blood test, may be utilized to detect the onset of diabetes in at-risk individuals.

These researchers say this discovery opens new avenues for preventing diabetes, particularly for at-risk people. A simple blood sampling followed by an inexpensive specific test could identify a potential diabetes onset in these people, prompting actions to be taken before the situation becomes irreversible.”

https://www.techexplorist.com/molecule-identify-development-diabetes/53106/
XX
XX
The T1D Exchange Registry is a research study conducted online over time, designed to foster innovation and improve the lives of people with T1D. The platform is open to both adults and children with T1D living in the U.S. Personal information remains confidential and participation is fully voluntary. Once enrolled, participants will complete annual surveys and have the opportunity to sign up for other studies on specific topics related to T1D. The registry aims to improve knowledge of T1D, accelerate the discovery and development of new treatments and technologies, and generate evidence to support policy or insurance changes that help the T1D community. By sharing opinions, experiences and data, patients can help advance meaningful T1D treatment, care and policy.
The registry is now available on the T1D Exchange website and is simple to navigate, mobile and user-friendly. For more information or to register, go to www.t1dregistry.org/stacey
XX
Abbott and Weight Watchers are teaming up. They’ve set up what they call a “strategic partnership” that will help people living with diabetes better understand and manage both their condition and their weight. The release says both companies are bringing their marketed products together to help patients, while also boosting their use. The partnership will start in earnest from next year and initially focus on the U.S.
https://www.fiercepharma.com/marketing/abbott-teams-weightwatchers-digital-diabetes-journey-health
XX
Next week we’re talking back to school! The wonderful diabetes educator Anna Sabino from Finding Smiles coaching will join me to talk 504, remote monitoring, supplies and lots more. The long format episode out right now is with Patients For Affordable Drugs about the bill that passed the Senate this week. The insulin copay cap was removed, but what does it really mean for medication prices?
Listen wherever you get your podcasts
That’s In the News for this week.. if you like it, please share it! Thanks for joining me! See you back here soon.

Aug 16, 2022

You may know the Inflation Reduction Act best for being the latest time an insulin price measure was NOT voted through. But supporters say there’s a lot here that will help patients save money, including those with diabetes.

We talk with Sarah Kaminer Bourland, Legislative Director of Patient for Affordable Drugs Now. She explains what this new plan will mean for those on and not on Medicare, debunk some of the talking points you might have heard and look ahead to what could be next for insulin pricing.

Share your story with P4AD: https://secure.everyaction.com/SvIaRhn3VEmVAkJ1ccQETA2

This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider.

Check out Stacey's book: The World's Worst Diabetes Mom!

Join the Diabetes Connections Facebook Group!

Sign up for our newsletter here

-----

Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners!
-----

Episode Transcription Below (or coming soon!)

Please visit our Sponsors & Partners - they help make the show possible!

*Click here to learn more about OMNIPOD*

*Click here to learn more about AFREZZA*

*Click here to learn more about DEXCOM*

Aug 12, 2022

Get caught up on the news and headlines around the diabetes community! The top stories in the last seven days: Senate Republicans nixed an insulin copay cap, but Democrats say they will revisit this issue in a few weeks, Dexcom pushed back their G7 timeline in the USA after the FDA asks for changes, once weekly basal insulin moves forward in trials. Plus, Beyond Type 1 is back in the NYC Marathon and much more!

Learn more about the T1D Exchange: https://t1dexchange.org/stacey/

Check out Stacey's book: The World's Worst Diabetes Mom!

Join the Diabetes Connections Facebook Group!

Sign up for our newsletter here

-----

Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners!
-----

Episode Transcription Below (or coming soon!)

Please visit our Sponsors & Partners - they help make the show possible!

*Click here to learn more about OMNIPOD*

*Click here to learn more about AFREZZA*

*Click here to learn more about DEXCOM*

 

Hello and welcome to Diabetes Connections In the News! I’m Stacey Simms and these are the top diabetes stories and headlines of the past seven days.
XX
In the news is brought to you by T1D Exchange! T1D Exchange is a nonprofit organization dedicated to improving outcomes for the entire T1D population.
https://t1dexchange.org/stacey/
XX
The copay cap on insulin may come back before the Senate in a few weeks. Senate Majority Leader Charles Schumer say he’ll bring tht issue back up.. after Republicans blocked it in a sweeping climate, inflation and health care package passed by the Senate on Monday. Speaking on MSNBC’s “The Rachel Maddow Show.” Schumer said, “We’re going to come back and make them vote on that again.” Seven Republicans still voted with all 50 Democrats, three short of the 60 votes needed, and it is possible more Republicans would support it if it came up as a standalone measure. It’s not clear if this would again be a copay cap or in fact a cap on the actual price of insulin for all, including the uninsured.
https://thehill.com/policy/healthcare/3594003-schumer-senate-will-vote-again-on-35-insulin-cap-after-gop-blocked-it/

XX
Dexcom is pushing back the timeline for a U.S. launch the G7. That’s after the FDA raised questions about the device’s software during a review. This has something to do with how the G7 and it’s smartphone apps deliver alarms to users. Looks like maybe a limited release in the 4th quarter of this year and full rollout in 2023 if there aren’t any other hiccups. As you likely know, the G7 is nearly 60-percent smaller than the G6, it’s transmitter and sensor all in one and has a much shorter warmup period. It’s been approved in Europe since March.

https://www.fiercebiotech.com/medtech/dexcom-resubmit-g7-glucose-monitor-software-fda-review-pushing-back-us-launch
XX
One type of once-a-week basal insulin gets the go ahead to move forward with clinical trials in the US. Gan & Lee Pharmaceuticals says it’s investigation drug called GZR4 is more stable with less day to day variation than once a day basal insulin. There are a few of these weekly insulins in trials, none yet approved. Gan & Lee is also doing trials of the drug in China where they are already a big player in the insulin market.
https://www.ganlee.com/detail/668.html
XX
XX
Good news for Senseonics, makers of the Eversense implantable CGM. Shares were up on second quarter earnings and future expectations. I don’t generally report on stock market moves of diabetes companies, but the past few years have been a bit iffy for Senseonics and there was speculation on whether this CGM option might not be available in the US. They partnered with Ascensia Diabetes Care and got the six month approval for Eversense earlier this year.
https://www.massdevice.com/senseonics-stock-q2-2022/
XX
A new call for comments to the FDA but the deadline is TODAY august 15 at midnight eastern time. I’m going to read directly from a post by Joanne Milo in the CGM in the Cloud off topic group. Joanne’s been a guest of the show and leads the loop and learn group – she writes. “We have until August 15, 2022 to provide comments on FDA changes to the way CGM display and alarm systems are regulated. This has implications for remote monitoring and automated insulin delivery systems, both commercial and DIY.
We request your assistance in helping the FDA and device providers (FDA considers software for treatment of disease to be a device) understand the benefits of real-time CGM access and the risks we carry by not having ubiquitous real-time access to our diabetes device data.
We hope you will choose to spend a moment to add your voice to the #WeAreNotWaiting chorus.
They provide some text which I’ll link up in the show notes as well as the links to this post and the FDA comment portal.
https://www.regulations.gov/commenton/FDA-2018-N-1910-0047?fbclid=IwAR2WAtGl3vjTUonamNdlBtAu_pg2-xQOVy8bSqG2peLCUz2eq8R8OgLqtHQ
https://www.facebook.com/groups/CGMITCOFFTOPIC
XX
The T1D Exchange Registry is a research study conducted online over time, designed to foster innovation and improve the lives of people with T1D. The platform is open to both adults and children with T1D living in the U.S. Personal information remains confidential and participation is fully voluntary. Once enrolled, participants will complete annual surveys and have the opportunity to sign up for other studies on specific topics related to T1D. The registry aims to improve knowledge of T1D, accelerate the discovery and development of new treatments and technologies, and generate evidence to support policy or insurance changes that help the T1D community. By sharing opinions, experiences and data, patients can help advance meaningful T1D treatment, care and policy.
The registry is now available on the T1D Exchange website and is simple to navigate, mobile and user-friendly. For more information or to register, go to www.t1dregistry.org/stacey
XX
Team of 50 individuals living with type 1 diabetes will raise awareness and funds for their chronic illness

SAN MATEO, Calif., (Aug. 3, 2022) – Going the extra mile this year, global diabetes nonprofit Beyond Type 1 was named an Official Charity Partner for the 2022 TCS New York City Marathon, taking place on November 6. Beyond Type 1 will be among the 500 official charity partners providing thousands of runners the opportunity to run in the world’s most popular marathon.

This year’s Beyond Type Run team includes nearly 50 runners across the United States, Canada, Ecuador and Australia, who are raising awareness and funds for type 1 diabetes as ambassadors for Beyond Type 1, showcasing how they live beyond their diagnoses and supporting crucial efforts and programs for others affected by this condition. First-time Marathon Runner Kyle Banks, known for his tour with the Broadway cast of The Lion King, is the team captain.

“The Beyond Type Run team displays the ultimate resilience and strength as they run the marathon. If it weren’t for the team jerseys or the technology attached to their bodies, you’d never know they were living with a chronic illness,” said Beyond Type 1 CEO Deborah Dugan. “We are grateful to them for helping us raise awareness, and we thank all of our sponsors for their generous support and donations to the team.”

Since 2017, Beyond Type 1 has had roughly 150 people with type 1 diabetes run the TCS New York City Marathon through the New York Road Runners (NYRR) Official Charity Partner Program.

“The TCS New York City Marathon serves as one of the world’s largest fundraising platforms supporting hundreds of charities and philanthropic efforts,” said Christine Burke, Senior VP of Strategic Partnerships, NYRR. “We are very proud to support Beyond Type 1 and the incredible impact they have made to the diabetes community as they raise important funds to support people with diabetes.”

The NYRR Official Charity Partner Program offers an opportunity for nonprofit organizations to raise funds to support their missions and services. Participating charities can offer guaranteed entry to runners who fundraise on their behalf.

Since its inception in 2006, the TCS New York City Marathon Official Charity Partner Program has raised more than $400 million for more than 1,000 worthy nonprofit organizations across the globe. Prior to the start of the official program, the New York City Marathon had served as an outlet for individual philanthropic runners since the 1980s.

https://beyondtype1.org/beyond-type-1-nyc-marathon-2022/
XX
Morgan Shepard book Morgan Shepherd
So happy to announce my book “ T1D Looks Like Us! A Type 1 Diabetes Story” is now available to order! I am so excited to share this piece of my heart with you ❤️ Rose was diagnosed with Type 1 Diabetes (T1D) when she was seven years old. Now she is nine and at times feels lonely because she doesn't know any other kids with T1D. With help from her mom, Rose meets people from all over the world who also live with T1D and have their own unique stories to share!

This book is intended to spark conversations about empathy, differences, and self-compassion. Through the text children will learn not only about Type 1 Diabetes but also about the diversity of people who are living bravely with T1D. The book is perfect for newly diagnosed children, siblings, and classrooms that have a student living with T1D.
XX
Next week I’m talking to the folks at Patients For Affordable Drugs about the bill that passed the Senate this week. The insulin copay cap was removed, but what does it really mean for medication prices? The episode out right now is our special 500th episode where I’m interviewed by news anchor Cristina Frank, who hosts the morning show at WMTW in Maine lives with type 1.
Listen wherever you get your podcasts
That’s In the News for this week.. if you like it, please share it! Thanks for joining me! See you back here soon.

Aug 9, 2022

I started Diabetes Connections back in the summer of 2015. I'm not sure I had a number of episodes in mind when I kicked off the show, I just knew I wanted to make a podcast for and about the diabetes community. Thanks for tuning in all this time! For episode 500, I've turned hosting duties over to Cristina Frank, a TV news anchor who lives with type 1.

We talk about how the episodes come together, what's worked (and what hasn't) and what I might add to the show going forward. We also think about how the community has changed and why the highest praise I could take for this show is that it's authentic. Thanks, all!!  -Stacey

Check out Stacey's book: The World's Worst Diabetes Mom!

Join the Diabetes Connections Facebook Group!

Sign up for our newsletter here

-----

Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners!
-----

Episode Transcription Below (or coming soon!)

Please visit our Sponsors & Partners - they help make the show possible!

*Click here to learn more about OMNIPOD*

*Click here to learn more about AFREZZA*

*Click here to learn more about DEXCOM*

Aug 2, 2022

Jeff Ryan has lived with type 1 for more than 50 years. But he also has what’s called an essential tremor. Part of the treatment for that included using powerful magnets, which made thinking about diabetes tech.. a little different for Jeff. He talks about being diagnosed as a toddler in 1971, and how treatment for both his tremor and his type 1 have changed.. as well as the power of community for both conditions.

He recently got his 50 year Joslin Medal and shares how a photo of him in front of a Christmas tree in 1971 played a role. That photo was a bit of a mystery to Jeff for a long time, since he was diagnosed in October.

2001 story about Jeff's brain surgery: https://www.webmd.com/brain/news/20010822/pacemaker-for-brain-effectively-stops-tremors

This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider.

Check out Stacey's book: The World's Worst Diabetes Mom!

Join the Diabetes Connections Facebook Group!

Sign up for our newsletter here

-----

Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners!
-----

Episode Transcription Below (or coming soon!)

Please visit our Sponsors & Partners - they help make the show possible!

*Click here to learn more about OMNIPOD*

*Click here to learn more about AFREZZA*

*Click here to learn more about DEXCOM*

Jul 29, 2022

It's In the News! The tops diabetes stories this week include: Australian scientists say they have a new way to restore insulin production using an existing and approved drug, Tandem rolls out bolus by phone for wider release and acquires Capillary Biomedical, an infusion set maker. Dexcom adds Spanish as a language option for the G6, a necklace is said to be able to monitor glucose levels and Netflix's Purple Hearts focuses on type 1 medical costs as a plot point.

Learn more about the T1D Exchange: https://t1dexchange.org/stacey/

Check out Stacey's book: The World's Worst Diabetes Mom!

Join the Diabetes Connections Facebook Group!

Sign up for our newsletter here

-----

Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners!
-----

Episode Transcription Below (or coming soon!)

Please visit our Sponsors & Partners - they help make the show possible!

*Click here to learn more about OMNIPOD*

*Click here to learn more about AFREZZA*

*Click here to learn more about DEXCOM*

 

Hello and welcome to Diabetes Connections In the News! I’m Stacey Simms and these are the top diabetes stories and headlines of the past seven days.

XX

In the news is brought to you by T1D Exchange! T1D Exchange is a nonprofit organization dedicated to improving outcomes for the entire T1D population.

https://t1dexchange.org/stacey/

XX

Australian scientists say they have a new way to restore insulin

production in pancreatic cells, using a drug that’s already approved for use in humans. In lab experiments on pancreatic stem cells from donors with type 1 diabetes, the team was able to activate them to begin expressing insulin by exposing them to a drug compound known as GSK126. These cells don’t normally produce insulin, but the drug let them functionally step into the shoes of the beta cells that had stopped working. In principle, a single course of this kind of drug over a few days could replace the need for regular insulin shots in diabetics.

The new treatment would work much faster, within a matter of days, and without the need for surgery. But perhaps the biggest advantage is that GSK126 is already approved by the US FDA and elsewhere in the world as a treatment for cancer. Its safety profile is already being assessed in clinical trials, which could reduce hurdles down the road for its use against diabetes.

That said, the scientists caution that it is still very early days. These experiments were conducted on cells in culture – not even in animals yet – so there’s still plenty of work to do. Nevertheless, it remains an intriguing new possible tool.

https://newatlas.com/medical/diabetes-breakthrough-insulin-production-existing-drug/

 

XX

Couple of big announcements from Tandem Diabetes this week. They’ve widened the roll out of their Mobile Bolus feature, now open to all customers with in-warranty tslim x2 pumps and compatible smart phones. Approved earlier this year, it has been available for a few weeks to a small group of users.

https://www.tandemdiabetes.com/products/software-apps/tconnect-mobile

XX

Tandem also announced it acquired infusion set developer Capillary Biomedical, an infusion set maker. To quote the press release: Capillary Biomedical’s unique extended wear infusion set technology is currently in development and not commercially available. The company designed its SteadiFlow seven-day-wear infusion set technology to significantly extend patient wear time to a week and maintain insulin stability. Capillary Biomedical received FDA investigational device exemption for the platform in January of this year.

https://www.drugdeliverybusiness.com/tandem-diabetes-acquires-capillary-biomedical-infusion/

XX

Dexcom is launching their G6 mobile app in Spanish. It is estimated that 11.8% of U.S. Latino adults have diagnosed diabetes. Dexcom says, “

“Launching the Dexcom G6 app in Spanish is a positive step toward improving health equity for individuals with diabetes who primarily speak Spanish.” To access the Dexcom G6 mobile app in Spanish, users need to install the latest version of the app and set their compatible iOS (v1.10.1) or Android (v1.10.0) smartphone* language to Spanish (any dialect/region). The app will automatically display in Spanish as long as the phone language is set to Spanish.

XX

 

Big issue for a diabetes app in the UK. CamAps FX is an automated insulin delivery system that works with Dexcom and Tandem. But Google has blocked it from the Play Store and won’t let it send text message alerts. Camdiab, the company behind it, is having to send the messages via another service and pay for each one individually.

Google said it doesn't allow any apps, other than the designated text message app on a device, to send SMS messages. CamAps FX spent 15 years in development by experts at Cambridge University and was the first system of its kind to be recommended by the NHS for use by children from the age of one, and pregnant people. We’ll see if the court of public opinion has any sway on what happens here.

 

https://www.bbc.com/news/technology-62184812

XX

 

Should we get excited about a new smart necklace said to measure glucose in sweat? Ohio State University recently presented the necklace, which has a clasp and pendant with biochemical sensors installed on the back so that when placed around the neck, it could capture the sweat and analyze glucose, serotonin, sodium, potassium, and hydrogen levels. In one experiment where people cycled  and drank sugary drinks, the sweat measured the increased glucose levels with a 98.9% accuracy. They didn’t really say what that means, though. Long way to go here but interesting idea.

 

https://www.sciencetimes.com/articles/38989/20220726/smart-necklace-track-wearers-health-status-98-9-accuracy-using.htm

XX

The T1D Exchange Registry is a research study conducted online over time, designed to foster innovation and improve the lives of people with T1D. The platform is open to both adults and children with T1D living in the U.S. Personal information remains confidential and participation is fully voluntary. Once enrolled, participants will complete annual surveys and have the opportunity to sign up for other studies on specific topics related to T1D. The registry aims to improve knowledge of T1D, accelerate the discovery and development of new treatments and technologies, and generate evidence to support policy or insurance changes that help the T1D community. By sharing opinions, experiences and data, patients can help advance meaningful T1D treatment, care and policy.

The registry is now available on the T1D Exchange website and is simple to navigate, mobile and user-friendly. For more information or to register, go to www.t1dregistry.org/stacey

XX

A new Netflix movie featuring type 1 is getting a lot of attention: Called Purple Hearts, it tells the story of Aspiring singer-songwriter Cassie Salazar (Sofia Carson). The synopsis says: Chasing her dreams isn’t exactly easy when she’s juggling multiple jobs and trying to keep her Type I diabetes at bay. Raised by an immigrant single mother and navigating a cruel health-care system, Cassie has seen how the “Land of the Free” has been everything but for people like her. After learning that Marine spouses get full health benefits and extra pay, Cassie comes up with an idea to marry one. Although the marriage is temporary, their true feelings for each other are revealed when an unexpected tragedy sends her now husband home earlier than expected.

I’ve reached out to the film makers. We’ll see if this one gets type 1 right.. but it sounds like they understand some of the health care system.

XX

Next week I’m talking to Jeff Ryan, who was diagnosed with type 1 as a little kid back in 1971. He also lives with an essential tremor, and was one of the first people to have brain surgery for it. Which was very successful.

The long format episode out right now is with Sebastien Sassville who tals about completed the race across America – a coast to coast cycling race in just 12 days.

Listen wherever you get your podcasts

That’s In the News for this week.. if you like it, please share it! Thanks for joining me! See you back here soon.

Jul 26, 2022

Sebastien Sasseville recently completed The Race Across America, a grueling 3-thousand miles coast to coast cycling event that riders must complete in only 12 days. That means pushing through not just diabetes, Sasseville lives with type 1, but also eating on the bike and sleeping just a few hours at a time.

Sasseville has been an ultra athlete for two decades now. We get more details about this race, why he wanted to do it and how he managed type 1 throughout.

More on Sassville here: https://sebinspire.com/en/

This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider.

Check out Stacey's book: The World's Worst Diabetes Mom!

Join the Diabetes Connections Facebook Group!

Sign up for our newsletter here

-----

Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners!
-----

Episode Transcription Below (or coming soon!)

Please visit our Sponsors & Partners - they help make the show possible!

*Click here to learn more about OMNIPOD*

*Click here to learn more about AFREZZA*

*Click here to learn more about DEXCOM*

Jul 22, 2022

Top stories In the News this week, United Healthcare announces changes to how they cover insulin for some, a new study looks at CGM use in people with type 2 over the age of 65, another company begins islet cell clinical trials, a new tool to treat diabetic neuropathy pain, gestational diabetes is on the rise, and more.

Learn more about the T1D Exchange: https://t1dexchange.org/stacey/

Check out Stacey's book: The World's Worst Diabetes Mom!

Join the Diabetes Connections Facebook Group!

Sign up for our newsletter here

-----

Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners!
-----

Episode Transcription Below (or coming soon!)

Please visit our Sponsors & Partners - they help make the show possible!

*Click here to learn more about OMNIPOD*

*Click here to learn more about AFREZZA*

*Click here to learn more about DEXCOM*

Hello and welcome to Diabetes Connections In the News! I’m Stacey Simms and these are the top diabetes stories and headlines of the past seven days.
XX
In the news is brought to you by T1D Exchange! T1D Exchange is a nonprofit organization dedicated to improving outcomes for the entire T1D population.
https://t1dexchange.org/stacey/
XX
Our top story.. United Healthcare says it will have no “out of pocket” expenses for insulin starting January first. It’s doing the same for other critical drugs like glucagon, epinephrine and albuterol. Looking into this a bit more, though, it’s not the boon it first seems. This only covers certain eligible patients. Stat news says about a quarter of United Healthcare’s patients will qualify but I saw a few commentators say it could actually be less than 5-percent. UnitedHealth Group shared that it earned $5.1 billion in profit for the second quarter of 2022.

https://kstp.com/kstp-news/top-news/united-healthcare-says-no-out-of-pocket-expenses-for-insulin/
XX
Not too surprising but a good study about people with type 2 using CGMs. This was for people using basal insulin only and over 65 years old. They found when given a CGM, their A1Cs went down an average of 1 full point with fewer lows. These are the kinds of studies that may seem obvious to us but that are needed to show insurers they need to cover.
https://www.liebertpub.com/doi/10.1089/dia.2021.0494
XX
New device approved to treat pain associated with diabetic peripheral neuropathy. The DyAnsys’ First Relief system is set behind the ear – its an adhesive, nothing surgical. It features three small, acupuncturelike needles that reach through the skin behind the ear to access the nervous system. Once in place, the device continuously emits low-level electrical pulses over the course of several days at a time; the FDA cleared the system for repeated treatments spanning up to eight weeks.
https://www.fiercebiotech.com/medtech/fda-clears-wearable-neurostimulator-dyansys-treat-pain-diabetic-nerve-damage
XX
Another company having success with islet cell transplants. ProtoKinetix announced they’re completely safety objectives and will start phase 1 clinical trials of their molecule PKX-001. Not much to report here yet, but I didn’t want to news of the Vertex/Viactye merger to over shadow that there are other efforts going on here.

https://www.businesswire.com/news/home/20220720005086/en/ProtoKinetix-Successfully-Completes-Phase-1-Clinical-Trials-for-the-Treatment-of-Type-1-Diabetes-in-Islet-Cell-Transplants
XX
Roche and Insulet settle their lawsuit.. this was a patent issue and both companies were suing each other. Insulet will give Roche 20-million dollars and Roche has agreed not to sue Insulet for five years. This was set to go to trial next week.
https://seekingalpha.com/news/3855728-insulet-to-pay-20m-to-settle-patent-lawsuit
XX
Gestational diabetes is on the rise, climbing 30% between 2016 and 2020, according to a new study by the Centers for Disease Control and Prevention.The CDC analysis showed that cases increased 13% during the first year of the pandemic alone, a much larger spike than the previous annual increases of about 5%. Experts say that the sharp increase during Covid may be because the disease accelerated people’s adoption of a sedentary lifestyle and led to pandemic-related physical and emotional stress. experts are concerned outcomes in 2021 may be worse, when Covid hit harder.
If anything, the authors and experts said, the new finding is likely an undercount. Relying on birth certificate data, which the CDC study did, can miss cases that are not captured by a physician on those forms. “If you think about it, somebody who’s doing 20 deliveries in a night, or ten deliveries in a night, is just kind of trying to get those reports and certificates out there,” said Morgan. “They’re not paying as much attention to some of those details.”

https://www.statnews.com/2022/07/20/as-diabetes-during-pregnancy-grows-more-common-experts-point-to-a-need-for-preventive-care/
XX
Right back to the news in a moment but first As I mentioned, The T1D Exchange Registry is an online research study, designed to harness the power of individuals with type 1 diabetes. It’s a research study conducted online over time, designed to foster innovation and improve the lives of people with T1D. Personal information remains confidential and participation is fully voluntary. Once enrolled, participants will complete annual surveys and have the opportunity to sign up for other studies on specific topics related to T1D. By sharing opinions, experiences and data, patients can help advance meaningful T1D treatment, care and policy Sign up at T1DExchange.org slash Stacey (that’s S-T-A-C-E-Y).
XX
/about-us/
XX

Next week on the podcast I’m talking to Sebastien Sasseville who recently completey the absolutely exhausting sounding Race Across America. We’ll talk about how you manage type 1 – and everything else – when you’re spending more than 20 hours a day on a bike for 12 days! The long format episode out right now is with the folks at Diabetes Wise – that’s a website to help you choose diabetes technology.. they’ve added information for doctors – this may help you educate your heathcare providers on why you want the pump or cgm system that you do..
Listen wherever you get your podcasts
That’s In the News for this week.. if you like it, please share it! Thanks for joining me! See you back here soon.

Jul 19, 2022

When you’re thinking about new diabetes technology, sometimes your endo is right there with you, keeping up on the latest & greatest. But if they’re not, a new resource could help. Diabetes Wise Pro includes more than just pump and CGM specs.

Stacey talks to Dr. Korey Hood, the co founder of DiabetesWise, a website that launched a few years ago to help consumers make more informed decisions around diabetes tech. We’ll talk about why they launched this new effort, who it’s for and how it could even change the prescription process.

More info https://providers.diabeteswise.org/#/

This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider.

Check out our previous interviews with Dr. Hood: https://diabetes-connections.com/?s=korey+hood

Check out the T1D exchange: https://t1dexchange.org/stacey/

Check out Stacey's book: The World's Worst Diabetes Mom!

Join the Diabetes Connections Facebook Group!

Sign up for our newsletter here

-----

Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners!
-----

Episode Transcription Below (or coming soon!)

Please visit our Sponsors & Partners - they help make the show possible!

*Click here to learn more about OMNIPOD*

*Click here to learn more about AFREZZA*

*Click here to learn more about DEXCOM*

Jul 15, 2022

Top stories in this news this week: Stem cell research Vertex company buys Viacyte, another company looking at stem cells for a functional cure for T1D, some tslim users are getting access to Tandem's new mobile bolus feature, One Drop shows a "health sensor" on its website, a study shows that screening for type 1 at very young ages could help detect most cases and much more!

Learn more about the T1D Exchange: https://t1dexchange.org/stacey/

Check out Stacey's book: The World's Worst Diabetes Mom!

Join the Diabetes Connections Facebook Group!

Sign up for our newsletter here

-----

Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners!
-----

Episode Transcription Below (or coming soon!)

Please visit our Sponsors & Partners - they help make the show possible!

*Click here to learn more about OMNIPOD*

*Click here to learn more about AFREZZA*

*Click here to learn more about DEXCOM*

Hello and welcome to Diabetes Connections In the News! I’m Stacey Simms and these are the top diabetes stories and headlines of the past seven days.
XX
In the news is brought to you by T1D Exchange! T1D Exchange is a nonprofit organization dedicated to improving outcomes for the entire T1D population.
https://t1dexchange.org/stacey/
XX
Our top story this week, Vertex buys Viacyte! For context, Vertex is the company that got all the headlines last fall – big article in the New York Times for a stem cell therapy that brought one person with type 1 off insulin completely. The FDA put them on hold but lifted that just last week. Vertex previously acquired Dr. Doug Melton's Semma.
Viactye is the company featured in the documentary "The Human Trial" - they're using CRISPR technology to keep the body from rejecting their stem cells. Both companies technology does NOT require immunosuppressive drugs and both say they are working toward a functional cure. Some experts are saying this will speed up that effort while critics worry that it eliminates the competitive aspect of the race. Sernova is still one separate company that has shown stem cell therapy can work.. I’ve got requests out to Viacyte to talk to us about all of this, so stay tuned.
https://investors.vrtx.com/news-releases/news-release-details/vertex-acquire-viacyte-goal-accelerating-its-potentially?fbclid=IwAR15qlFSBsBR89blzXymyIGL3tW5C64QtdHpwq7a5fdjmv2q6JmfoTIpm-k
XX
If we widely screened kids for type 1 at certain ages, a new study suggests, it would identify most of those who go on to develop it by their teen years. These researchers looked at screening for the type 1 autoantibodies at ages 2 and 6. This included nearly 25-thousand children from Europe and US. One issue in this study, funded by JDRF, all the participants in the combined dataset had genetic risk factors for the disease or a relative with type 1 diabetes, in whom performance is expected to be higher. It also included almost exclusively kids of northern European ancestry.
https://www.medscape.com/viewarticle/976992
XX
Tandem bolus by phone is slowly rolling out. This week, the T:Connect app was updated in the The t:connect app was updated and emails started arriving for those notified they were part of the early release groups. I did see some reports of people not yet getting the email but seeing the update in their portal so be sure and check. Mobile Bolus is reportedly available for those using Control IQ and Basal IQ. It’s worth noting that for those outside the US there really is no timeline, but Tandem has previously said they’re going to replace t:connect with a new system that will debut outside the US first. By the way, I got my email this morning, but Benny is still at camp for three more weeks so it'll be a bit before we do the update!
XX
Interesting look at teens and young adults with type 1.. the early morning psychosocial state may explain a proportion of their daily variance in time in range. The study included 88 participants aged between 14 and 26 years, 56-percent of whom were women. This is tough to quantify but they had the participants complete an engagement prediction survey and set a diabetes management goal for the day when they woke up, and also completed an evening survey. These questions were about mood, motivation, control beliefs, social support, stress, general health, self-esteem, and perceived need for assistance.

Of note, lower morning glucose levels correlated with measures of good sleep, high motivation, and good health, whereas higher morning glucose levels were associated with illness and feeling the need for support.
https://www.medwirenews.com/diabetes/morning-mindset-daily-glucose-fluctuations-young-people-diabetes/23255450
XX
Good catch by our friend Nerdabetic over on Twitter.. One Drop plans to enter what they’re calling the continuous health sensing market with a daily disposable, minimally invasive biosensor in development. They say this is designed to provide greater flexibility and insights for people living with diabetes compared to blood glucose monitor (BGM) fingersticks alone. The availability of our continuous health sensor is subject to receipt of clearance or approval from the U.S. Food and Drug Administration. Pending regulatory approval and commercial adoption, we believe integrating the One Drop health sensor with our existing digital solution, One Drop Premium, should augment proven outcomes and yearly cost savings for members living with diabetes and other chronic conditions.
https://onedrop.today/blogs/blog/bgm-vs-cgm?utm_source=twitter&utm_medium=social-organic&utm_campaign=social-campaign_jul-2022&utm_content=blog
XX
Navitus Health Solutions, which is owned by Costco & SSM Health – has joined CivicaScript as a founding member. CivicaScript was created in 2020 to bring affordable versions of common but high-priced generic medicines to market. Earlier this year they announced they would be adding insulin to that list, but it likely won’t be available for at least two years. This partnership would seem to insure the lower cost insulin will be available at Costco pharmacies, which you don’t have to have a membership to use.

https://www.businesswire.com/news/home/20220713005349/en/Navitus-Health-Solutions-Joins-CivicaScriptTM-to-Further-Availability-of-Lower-Cost-Generic-Medications/?fbclid=IwAR0vBF0YlCo9ZJ-9Yd0nLag_Mjuf8s4YpnR9IJVudvVGDR1Rj508HSd_kXw
XX
Right back to the news in a moment but first As I mentioned, The T1D Exchange Registry is an online research study, designed to harness the power of individuals with type 1 diabetes. It’s a research study conducted online over time, designed to foster innovation and improve the lives of people with T1D. Personal information remains confidential and participation is fully voluntary. Once enrolled, participants will complete annual surveys and have the opportunity to sign up for other studies on specific topics related to T1D. By sharing opinions, experiences and data, patients can help advance meaningful T1D treatment, care and policy Sign up at T1DExchange.org slash Stacey (that’s S-T-A-C-E-Y).
XX
The Food and Drug Administration received more than a thousand comments—mainly from diabetes patients and their family members—in response to draft cybersecurity guidance. These are for staff to use when processing submissions from medical-device manufacturers.

“Please do not let medical device manufacturers use cybersecurity as a pretense to prevent me from accessing my OWN devices,” reads one entry from a sample of the comments FDA posted to the docket on the guidance.

Howard Look, CEO of Tidepool is quoted in some of the article around this. Tidepool provides software that allows patients to see their data and better manage the disease. And supporters are working to make Tidepool Loop the first FDA approved app for more convenient automated insulin delivery.
“Following best practices for cybersecurity does not need to imply blocking patient users from accessing their own data or controlling their own devices,” the comments read. “Tidepool asserts there is a risk that the FDA guidance will be interpreted or misinterpreted to suggest restriction of access by the patient user is appropriate or encouraged. The FDA can mitigate this risk by clearly stating a patient user’s access to and use of their own device can be considered authorized access, and should not be considered a cybersecurity threat.”
With a 90-day public comment period ending Thursday, the FDA will now begin the process of finalizing cybersecurity guidance for its pre-market submissions, according to a notice in the Federal Register.

https://www.nextgov.com/cybersecurity/2022/07/diabetes-patients-flood-fda-comments-cybersecurity-medical-devices/374020/
XX

Congrats to the team over at Divabetic Podcast – which celebrates 12 years this month! Divabetic was inspired by the late R&B legend, Luther Vandross, and founded in 2005 by his long-time assistant, Max “Mr. Divabetic” Szadek. It’s now a national nonprofit organization that uses highly engaged, non-traditional virtual programs, videos and podcasts to promote prevention, early action and education. Congrats to Max and the entire team!
https://divabetic.org/about-us/
XX
Next week you’ll hear from the folks at Diabetes Wise – that’s a website to help you choose diabetes technology.. they’ve added information for doctors – this may help you educate your heathcare providers on why you want the pump or cgm system that you do.. the long format episode out right now is all about campviews, a new system that lets diabetes camps see every camper’s CGM all at once.
Listen wherever you get your podcasts
That’s In the News for this week.. if you like it, please share it! Thanks for joining me! See you back here soon.

Jul 12, 2022

It’s that time of year - diabetes camps are in full swing. As remote monitoring technology changes, many camps are adapting as well. There’s a new system that lets camp staff monitor everyone’s CGM, all at once. That’s Sarah Gleich, executive director of the Nevada California Diabetes Association. We’ll find out more about what’s called CampViews, where it’s already in place, how it’s going and whether it’ll change diabetes camp for good. This technology could also make a big difference for hospitals, nursing homes and other health facilities.

This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider.

Check out Stacey's book: The World's Worst Diabetes Mom!

Join the Diabetes Connections Facebook Group!

Sign up for our newsletter here

-----

Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners!
-----

Episode Transcription Below (or coming soon!)

Please visit our Sponsors & Partners - they help make the show possible!

*Click here to learn more about OMNIPOD*

*Click here to learn more about AFREZZA*

*Click here to learn more about DEXCOM*

Jul 5, 2022

Her daughter was diagnosed during the first year of COVID.. now Katie Roseborough is looking to help other moms by sharing her story. Katie’s started a podcast; she talks about why and shares stories about her family’s experience. She has three kids, only one with type 1.

More about Katie here https://www.sugarmamaspodcast.com/

Book presales are open! "STILL The World's Worst Diabetes Mom" will be out this fall. Order now and use promo code "Earlybird" to save $5!

https://diabetes-connections.com/book-store/

You can also save $5 on the first "World's Worst Diabetes Mom" at that link, just use "Earlybird" at checkout.

This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider.

Check out Stacey's book: The World's Worst Diabetes Mom!

Join the Diabetes Connections Facebook Group!

Sign up for our newsletter here

-----

Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners!
-----

Episode Transcription Below (or coming soon!)

Please visit our Sponsors & Partners - they help make the show possible!

*Click here to learn more about OMNIPOD*

*Click here to learn more about AFREZZA*

*Click here to learn more about DEXCOM*

Jul 1, 2022

Top stories in the news this week: researchers are testing an injection to help prevent type 1 diabetes while not harming the immune system, a new study looks at older adults and CGM use, help for pharmacists when it comes to prescribing CGM and a new group takes over the Lilly Diabetes Journey Award Medals. Plus, amazing feats of endurance from ultra athletes with type 1 diabetes.

Learn more about the T1D Exchange: https://t1dexchange.org/stacey/

Check out Stacey's book: The World's Worst Diabetes Mom!

Join the Diabetes Connections Facebook Group!

Sign up for our newsletter here

-----

Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners!
-----

Episode Transcription Below (or coming soon!)

Please visit our Sponsors & Partners - they help make the show possible!

*Click here to learn more about OMNIPOD*

*Click here to learn more about AFREZZA*

*Click here to learn more about DEXCOM*

Hello and welcome to Diabetes Connections In the News! I’m Stacey Simms and these are the top diabetes stories and headlines of the past seven days.
XX
In the news is brought to you by T1D Exchange! T1D Exchange is a nonprofit organization dedicated to improving outcomes for the entire T1D population.
https://t1dexchange.org/stacey/
XX
Interesting new study looking at preventing type 1. The drug, currently known as IMCY-0098, blocks the immune system response that is thought to be the trigger. Very early on here, the Oxford scientists who are part of the study say it will likely be at least ten years before they’ll be able to bring it to market, if it works. One of the most promising aspects is that the injection seems to only target production of cells that damage the immune system, so it doesn’t seem to affect the body’s ability to protect itself against other infections.

https://www.dailymail.co.uk/health/article-10952755/Type-1-diabetes-stopped-strikes-thanks-simple-jab.html
XX
No surprise but glad this is being looked at. Older adults with type 1 diabetes using CGMs for the first time had lower A1Cs AND fewer lows. This study called WISDM - Wireless Innovation for Seniors with Diabetes Mellitus (WISDM) followed adults over 60 for six months. These researchers say the benefits of CGM combined with recently improved Medicare coverage should serve to increase adoption of CGM as standard of care in all adult populations, especially older people who are at increased risk of hypoglycemia.
https://www.healio.com/news/endocrinology/20220627/cgm-improves-time-in-range-reduces-hba1c-for-older-adults-with-type-1-diabetes
XX
New resource thanks to the Helmsley Trust. This is for pharmacists and it’s hoped it will expand patient access to CGMs. The release says Involving pharmacists in providing access is especially important for rural communities where they may be the most reachable healthcare professionals given the lack of diabetes specialists across the U.S. The guide was developed by the American Pharmacists Association and its Foundation
http://ow.ly/zZ3c50Jz20f
XX
Looks like the Lilly Diabetes Journey Award Medals are getting a second life. As we reported back in January, after nearly 50 years, Lilly decided to end the program which gives a small medal for 10,25, 50 and 75 years of living with diabetes. The group Children with Diabetes – best known for putting on the Friends for Life Conference has taken it over. They’ll now be called the CWD Journey Awards. You don’t have to attend one of their conferences to get one and there is no cost. I’ll give you the link to learn more and order one.
XX
The vets and keepers at the Royal Zoological Society of Scotland (RZSS) diagnosed the first reported case of diabetes in a giant anteater.
Stephanie Mota, resident veterinary surgeon at RZSS said: “Keepers first discovered something was wrong when Nala was losing weight despite eating the same amount, or sometimes even more, than usual.
“We carried out a full health check under general anaesthetic, running lots of tests and found that Nala has type 1 diabetes.”
While the condition is known to occur in domestic cats, dogs and in tamanduas (Tuh-man-doo-uhs) in the wild, no other cases have been reported in giant anteaters. BTW a Tu-man-doo-uh is a smaller anteater and I spent far too much time today watching videos of them because I had never head of them and they are amazing.
Dexcom donated the CGM to the Zoo’s charity. The story I read here says. Due to her lovely personality, Nala is the ideal candidate for this technology which helps us, and her amazing team of keepers, manage her condition in the best possible way.
https://www.edinburghnews.scotsman.com/news/people/edinburgh-zoo-monitor-uks-first-diabetic-giant-anteater-with-blood-glucose-monitor-usually-used-on-humans-3749422
XX
Right back to the news in a moment but first As I mentioned, The T1D Exchange Registry is an online research study, designed to harness the power of individuals with type 1 diabetes. It’s a research study conducted online over time, designed to foster innovation and improve the lives of people with T1D. Personal information remains confidential and participation is fully voluntary. Once enrolled, participants will complete annual surveys and have the opportunity to sign up for other studies on specific topics related to T1D. By sharing opinions, experiences and data, patients can help advance meaningful T1D treatment, care and policy Sign up at T1DExchange.org slash Stacey (that’s S-T-A-C-E-Y).
XX
Some great stories from our amazing community. First, Sebastien Sassevile completed the world's toughest ultra-cycling race, the Race Across America. It took 12 days and over 3-thousand miles. Sasseville who lives with type 1 basically spent 20 hours a day on his bike. He’s the first person with type 1 to finish this grueling race.
--
Don Muchow told us he was going to do it and the 60 year old has finished a 10k swim around Key West. I spoke to Muchow just after his 2021 Disney to Disney run – that’s Disneyland in California to Disneyworld in Florida and he alluded to doing this race next. I’ve linked up his race report blog.. it’s a very interesting read, especially how he treated a high blood glucose with more carbs. He came in second overall and first male in any age group.

https://swimswam.com/60-year-old-iron-man-don-muchow-swims-around-key-west-for-diabetes-awareness/
https://t1determined.org/event-report-swim-around-key-west-10k/?fbclid=IwAR1U7XdI4_uw9OSe994TKuu7IuYjWC8FwHhby0Pm-RRzDIYAd9pGCMj6AD0
XX
And finally, another former guest Dr. Nat Strand who works at the Mayo Clinic debuted a film she made with colleagues. It tells the story of what it is to be Black at Mayo Clinic, in healthcare, in America. Dr. Strand says, “By providing a platform for 12 courageous individuals to share their realities, we hope to move viewers toward active antiracism and start the conversation for many to continue.”

 

XX
Next week you’ll hear from Katie who started a podcast when she didn’t hear the diabetes show she wanted.. that sounds familiar. You may know her online as Sugarmama Podcast. The long format episode out right now is all about the new documentary regarding stem cell research, talking to the director of “The Human Trial” i
Listen wherever you get your podcasts
That’s In the News for this week.. if you like it, please share it! Thanks for joining me! See you back here soon.

Jun 28, 2022

This summer we get a behind the scenes look at the evolution of stem cells as a functional cure for type 1. The Human Trial is new documentary that follows the process and the filmmakers are incredibly optimistic about what they’ve seen. Co-director Lisa Hepner lives with type 1. She’s says she’s knows to be careful about “the cure in five years’ kind of statements but is convinced this is the real deal. We’ll talk about the the film, the process, the science and a lot more.

Listen to our first interview with Lisa Hepner from 2016

This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider.

Check out Stacey's book: The World's Worst Diabetes Mom!

Join the Diabetes Connections Facebook Group!

Sign up for our newsletter here

-----

Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners!
-----

Episode Transcription Below (or coming soon!)

Please visit our Sponsors & Partners - they help make the show possible!

*Click here to learn more about OMNIPOD*

*Click here to learn more about AFREZZA*

*Click here to learn more about DEXCOM*

Jun 24, 2022

It’s “In the News..” got a few minutes? Get caught up! Top stories this week: The US Senate may have a bipartisan plan to lower the price of insulin for the insured, nasal insulin is tested to reduce the risk of Alzheimer's in people with diabetes, two interesting studies about sleep and diabetes, and more!

Check out Stacey's book: The World's Worst Diabetes Mom!

Join the Diabetes Connections Facebook Group!

Sign up for our newsletter here

-----

Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners!
-----

Episode Transcription Below (or coming soon!)

Please visit our Sponsors & Partners - they help make the show possible!

*Click here to learn more about OMNIPOD*

*Click here to learn more about AFREZZA*

*Click here to learn more about DEXCOM*

Hello and welcome to Diabetes Connections In the News! I’m Stacey Simms and these are the top diabetes stories and headlines of the past seven days.
XX
In the news is brought to you by T1D Exchange! T1D Exchange is a nonprofit organization dedicated to improving outcomes for the entire T1D population.
https://t1dexchange.org/stacey/
XX
Two Senators have unveiled legislation aimed at lowering the cost of insulin, but not for the uninsured. This is a bipartisan bill that would lower patietn’s cost to 35-dollars a month, for those with commercial insurance and on Medicare. It would eliminate the rebates drug companies pay to negotiators known as pharmacy benefit managers if the drug company kept the overall price of insulin below a certain level. Democrats are also in the midst of talks on a party-line package on President Biden’s economic agenda that would likely include reductions in insulin costs as well as broader measures aimed at lowering drug prices, which could complicate any push for a stand-alone insulin measure. This change has enormous support among Americans, but can’t seem to get any real traction in Washington despite who’s in power. We’ll see what happens..

https://thehill.com/policy/healthcare/3531954-bipartisan-pair-of-senators-unveils-bill-to-lower-insulin-costs/
XX
Nasal insulin doesn’t look like it works too well on diabetes, but a new study shows it may help to slow age related mental decline. This study found that after 12 months of once daily intranasal insulin, people with diabetes in the study performed better on cognitive tests than those diabetics in the placebo group. The non-diabetic group receiving the intranasal insulin also displayed improvements on decision making and verbal memory tests compared to non-diabetics in the placebo group.
The biggest improvements in the non-diabetic group were seen in those subjects who started the trial in a prediabetic state. This suggests the treatment may be most effective at slowing cognitive decline in either diabetics or those with prediabetes.
https://newatlas.com/health-wellbeing/insulin-nasal-spray-cognitive-decline-dementia-clinical-trial/
XX
Go to sleep, and don’t breathe too much. Researchers in the U.K. will test hypoxia to treat type 2 diabetes. Hypoxia is a state where the body does not receive sufficient amounts of oxygen.

Multiple studies have shown that hypoxia improves blood sugar levels and aids in weight loss. Although scientists do not fully understand how this works, it is suggested that hypoxia burns more calories in the body, resulting in lower appetites in individuals. These researchers want to recruit volunteers so they can figure out why. Each volunteer will be provided with a sleeping tent in which they have to sleep – at home - for 10-day periods on two separate occasions. For one of they nights, they oxygen levels will be set to 15 percent. That sounds ridiculous, but, the air we breathe right now is only about 21% oxygen. 15-percent is pretty typical for find at high altitudes or inside an airplane.
https://interestingengineering.com/lose-weight-while-asleep
XX
Another look at sleeping and type 2.. an exposure to light may increase the risk. Big sleep study at Northwestern University found that exposure to any amount of light during the sleep period was correlated with the higher prevalence of diabetes, obesity and hypertension in both older men and women. A study published earlier this year by the same team found for healthy adults in their 20s. Sleeping for only one night with a dim light, such as a TV set with the sound off, raised the blood sugar and heart rate.
An elevated heart rate at night has been shown in prior studies to be a risk factor for future heart disease and early death, while higher blood sugar levels are a sign of insulin resistance, which can ultimately lead to type 2 diabetes.
Instead of pulling people into a sleep lab, the new study used a real-world setting. Researchers gave 552 men and women between the ages of 63 and 84 an actigraph, a small device worn like a wristwatch that measures sleep cycles, average movement and light exposure.
Fewer than half of the adults in the study got five hours of darkness at night.
those who had higher amounts of light at night were also the most likely to have diabetes, obesity or hypertension."
Strategies for reducing light levels at night include positioning your bed away from windows or using light-blocking window shades. Don't charge laptops and cellphones in your bedroom where melatonin-altering blue light can disrupt your sleep. If low levels of light persist, try a sleep mask to shelter your eyes.
In that case, consider using nightlights positioned very low to the ground, and choose lights with an amber or red color. That spectrum of light has a longer wavelength, and is less intrusive and disruptive to our circadian rhythm, or body clock, than shorter wavelengths such as blue light.

https://www.cnn.com/2022/06/22/health/light-exposure-sleep-study-wellness/index.html
XX
https://medicalxpress.com/news/2022-06-reveals-key-diabetes-drug-nature.htmlXX
XX
Nice story out of Kansas City where Chiefs offensive tackle Orlando Brown Jr. publicly enrolled himself in a TrialNet study. His brother lives with type 1 and his father died of DKA without knowing he had diabetes. Brown said he hopes participating in the trial will help others while helping himself and his family.

https://www.kshb.com/sports/chiefs-orlando-brown-jr-enrolls-in-trialnet-study-for-type-1-diabetes
XX
Right back to the news in a moment but first As I mentioned, The T1D Exchange Registry is an online research study, designed to harness the power of individuals with type 1 diabetes. It’s a research study conducted online over time, designed to foster innovation and improve the lives of people with T1D. Personal information remains confidential and participation is fully voluntary. Once enrolled, participants will complete annual surveys and have the opportunity to sign up for other studies on specific topics related to T1D. By sharing opinions, experiences and data, patients can help advance meaningful T1D treatment, care and policy Sign up at T1DExchange.org slash Stacey (that’s S-T-A-C-E-Y).
XX
Congrats to the great team of Ginger Vieira and Mike Lawson on their newest book. Ain’t Gonna Hide My T1D. Sherry the Sheep loves to draw and play basketball, but she’s worried about what her friends will think if they see her insulin & CGM. Ginger and Mike are long time advocates who both live with type 1. This is their 3rd children’s book together and I think they do a great job of balancing fun and education.
https://smile.amazon.com/Aint-Gonna-Hide-My-T1D/dp/B0B455DL45/ref=sr_1_4?qid=1655748198&refinements=p_27:GingerVieira&s=books&sr=1-4&text=GingerVieira
XX
And finally, The Human Trial premieres this weekend. This is a documentary all about stem cell transplantation as a functional cure for type 1. I first spoke to the people behind this film back in 2016 when they were well underway. The movie follows the first two patients in the Viacyte trials. You can host your own screening.. I’ll link up more information – as I do with all of these stories - in the show notes.
XX
And.. The Human Trial will be subject of next week’s long format show. My interview with Lisa Hepner is a follow up to the one six years ago when we first discussed this project. We go into the details of stem cell research, what changed and what she’s seen behind the scenes. The current long-format episode out now is all about Skirt My Pump, an ingenious idea from a women who’s lived with type 1 for 40 years and got fed up with figuring out where to put her pump.
Listen wherever you get your podcasts
That’s In the News for this week.. if you like it, please share it! Thanks for joining me! See you back here soon.

Jun 21, 2022

Wearing an insulin pump can be a huge help when it comes to managing diabetes, but finding a place to put it can be difficult. Women’s clothing in particular, isn’t great for storing stuff. Erin Calhoun-Dulaney has lived with type 1 for 40 years and she finally got fed up enough to create her own product. We’ll talk about Skirt my Pump, her experience with T1D and her career as a Hollywood publicist.

Stacey also has information about Tandem's Mobile Bolus limited roll out. Click here to find out more and sign up. 

This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider.

Check out Stacey's book: The World's Worst Diabetes Mom!

Join the Diabetes Connections Facebook Group!

Sign up for our newsletter here

-----

Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners!
-----

Episode Transcription Below (or coming soon!)

Please visit our Sponsors & Partners - they help make the show possible!

*Click here to learn more about OMNIPOD*

*Click here to learn more about AFREZZA*

*Click here to learn more about DEXCOM*

Jun 17, 2022

It’s “In the News..” got a few minutes? Get caught up! Top stories this week: Tandem Diabetes announces a limited launch of their mobile bolus feature (signup below), researchers look at how Basaglar stacks up, new guidelines for diabetes in the hospital, a T1D extreme athlete bikes across the USA and more

Learn about the T1D Exchange!

Check out Stacey's book: The World's Worst Diabetes Mom!

Join the Diabetes Connections Facebook Group!

Sign up for our newsletter here

-----

Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners!
-----

Episode Transcription Below (or coming soon!)

Please visit our Sponsors & Partners - they help make the show possible!

*Click here to learn more about OMNIPOD*

*Click here to learn more about AFREZZA*

*Click here to learn more about DEXCOM*

Hello and welcome to Diabetes Connections In the News! I’m Stacey Simms and these are the top diabetes stories and headlines of the past seven days. we go live on social media first and then All sources linked up at diabetes dash connections dot com when this airs as a podcast.
XX
In the news is brought to you by T1D Exchange! T1D Exchange is a nonprofit organization dedicated to improving outcomes for the entire T1D population.
https://t1dexchange.org/stacey/
XX
Tandem’s mobile bolus feature is in limited release. Approved earlier this year, they’ve released the feature to a very small number of users and are expecting a wider, still limited, release in the next few weeks. This is the feature that allows you to bolus by phone and use the t-connect app to see pump data on your phone as well. It’s not full pump control via phone, but it’s a big step forward in terms of convenience for users and for Tandem’ next product, the MOBI pump – which won’t have a screen and will have full phone control. I’m asking Tandem to come on the show and share more about the features and how it works. It’s interesting that you can’t dismiss alerts and alarms from the app and must do so on the pump itself. I’ll link up the site you need to sign up for the limited release. You will need to update the software on your tslim x2 pump and take some additional online training. This is US only.
https://www.tandemdiabetes.com/landing-pages/remote-bolus
XX
The Eversense E3 gets European approval. This is a partnership between Ascensia diabetes care and Senseonics. The E3 is the six month version of the implantable CGM system. It’s also approved for insulin treatment decisions, which is a switch from the XL version already available in Europe. The E3 was approved in the US earlier this year and should be distributed in Europe in the fall.
https://finance.yahoo.com/news/ascensia-diabetes-care-announces-european-060000125.html
XX
XX
New guidelines for treating diabetes in the hospital. This is from the Endocrine Society, which last updated their guidelines ten years ago. New this time around, hospital use of continuous glucose monitoring and insulin pump therapy, providing inpatient diabetes education as part of a comprehensive diabetes discharge-planning process, use of noninsulin glucose-lowering therapies, and more.
Adult patients with diabetes or newly recognized hyperglycemia account for greater than 30% of noncritically ill hospitalized patients.
https://www.clinicaladvisor.com/home/topics/endocrinology-information-center/endocrine-society-issues-new-guidelines-for-hospitalized-patients-with-diabetes/
XX
Works just as well and costs less.. that’s the upshot of a new study on Basaglar, the copycat insulin to Lantus when it comes to type 2 diabetes. The findings come from 14 commercial health plans and Medicare Advantage plans. Basaglar was approved as a biosimilar insulin glargine by the US Food and Drug Administration in 2015. This was a large study of thousands of patients and also showed that there was better adherence to Basaglar, no reason for that was given, but it could be the lower cost.
https://www.medscape.com/viewarticle/975440
XX
Right back to the news in a moment but first As I mentioned, The T1D Exchange Registry is an online research study, designed to harness the power of individuals with type 1 diabetes. It’s a research study conducted online over time, designed to foster innovation and improve the lives of people with T1D. Personal information remains confidential and participation is fully voluntary. Once enrolled, participants will complete annual surveys and have the opportunity to sign up for other studies on specific topics related to T1D. By sharing opinions, experiences and data, patients can help advance meaningful T1D treatment, care and policy Sign up at T1DExchange.org slash Stacey (that’s S-T-A-C-E-Y).
XX
Very early but Swedish researchers have now identified a molecule that helps stimulate the growth of new insulin-producing cells, and uncovered how it works. These researchers looked at a molecule known as CID661578 and found that it binds to a protein called MNK2. In doing so, it allows two other proteins to interact at higher levels, which ultimately leads to greater beta cell regeneration. The team tested their molecule in zebrafish, and found that it lowered blood glucose levels when compared to a control group. In pig pancreas cells grown in the lab, the molecule was shown to trigger the formation of new beta cells, while human pancreas organoids given the molecule produced more insulin.
Long way to go, but still interesting.
XX
Type 1 Endurance athlete Sebastien Sasseville is taking part in the race across American this week. Called the world’s premier ultra endurance race, it’s literally a cycling event from the West Coast to the East Coast with a maximum lenthg of 12 days. That mean they have to cover about 275 miles every day.
The original concept runs all the way back to 1887 when newspaperman George Nellis rode across the country via railroad routes in 80 days. The more modern version began in the 1970s, when John Marino decided to see how fast he could get across the country on a bicycle. The first head-to-head race came in 1982, and there were four starters.
It's been called a brutal version of the tour de France. Sasseville has been on the show before and I’ll catch up with him after he recovers here. He’s been up Mt Everest, ran across Canada and did the brutal race across the Sahara Desert. He’s sponsored by Tandem.
https://cyclingtips.com/2022/06/how-to-watch-race-across-america-raam-route-map-elevation-live-dot-watching/
XX
On this week’s long format episode, you’ll hear my conversation with Sernova’s CEO all about their cell therapy and the search for a functional cure for type 1. Next week, a little less technology.. a fun conversation with a woman frustrated with the limits of wearing her pump, especially with skirts, so she found a new solution.
Listen wherever you get your podcasts
That’s In the News for this week.. if you like it, please share it! Thanks for joining me! See you back here soon.

Jun 14, 2022

Big news from Sernova, one of the companies hoping that implantable stem cells will be a functional cure for diabetes. They recently announced that the first person in their trials with type 1 is completely off injected or infused insulin – and is making their own.

Stacey talks to Dr. Philip Toleikis, Sernova’s president and CEO. He explains how their process differs from some of the other companies looking at stem cells, talks about their partnerships and shares more about the patients doing well in this clinical trial.

This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider.

Check out Stacey's book: The World's Worst Diabetes Mom!

Join the Diabetes Connections Facebook Group!

Sign up for our newsletter here

-----

Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners!
-----

Episode Transcription Below (or coming soon!)

Please visit our Sponsors & Partners - they help make the show possible!

*Click here to learn more about OMNIPOD*

*Click here to learn more about AFREZZA*

*Click here to learn more about DEXCOM*

1 « Previous 3 4 5 6 7 8 9 Next » 26